ClinicalTrials.gg
CompletedNCT02174432Updated May 21, 2025Results posted

Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis

A Phase 2/3 interventional study of nalbuphine HCl ER in Prurigo Nodularis, Nodularis Prurigo and Prurigo, sponsored by Trevi Therapeutics. Completed at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-21.

Sponsored by Trevi Therapeutics · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Prurigo with a site in Germany — 2 open to participants now, 7 under way, 3 of them phase 3. Prurigo · Germany.

Enrollment
14th of 18
36 · median 143
Started
2015
with 1 other
Phase 2/3
3 of 20
none open now
Registered
2nd of 20
by date
Lead sponsor
3 of 20
Trevi Therapeutics

Among the 20 studies in Prurigo with a site in Germany, this one is the 14th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2015, is one of 3 in phase 2/3, and was the 2nd registered.

Prurigo

38 studies on the registry are indexed under Prurigo; 10 are open to participants now.

Browse Prurigo studies →

Open to participants now

2 of the 20 studies in Prurigo with a site in Germany are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 7 Prurigo studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Prurigo with a site in Germany, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 50 weeks.

03

Conditions studied

  • Prurigo Nodularis
  • Nodularis Prurigo
  • Prurigo

Browse trials for

Keywords

  • Itch
  • Chronic Itch
  • Nalbupine
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject completed participation in the TR03 study

Exclusion criteria

Exclusion Criteria:

  • Medical condition or other factors that in the opinion of the Investigator may interfere with the conduct of the study.
  • Subject is a pregnant or lactating female
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    nalbuphine HCl ER

    nalbuphine HCl ER

    Drug: nalbuphine HCl ER

Interventions

  • nalbuphine HCl ER BID for up to 50 weeks

    Also known as: nalbuphine

06

What researchers measure

Primary outcomes

  1. Overall Incidence and Nature of Treatment Emergent Adverse Events (TEAEs)

    Incidence of adverse events is calculated based on events observed on or after the date of first dose, where incidence is defined as the number of subjects who reported one or more events of a particular adverse event divided by the number of subjects who received at least one dose of investigational product. Overall incidence is the proportion of subjects who had one or more adverse events of any type and nature pertains to the incidence of individual events coded by MedDRA nomenclature. An additional consideration was to evaluate incidence of adverse events by dose achieved but this was not done as subjects achieved a maximum dose during the study that varied and, per protocol, dosing could be modified per the investigator, during the course of this extension to TR03. In addition, TR03EXT involved a dose titration whereas events could have been reported well before a subject achieved some partciular dose level. Consequently, such a presentation would have been impossible to discern.

    Time frame: 50 weeks

07

Results

Posted Oct 23, 2020

Participant flow

Participant flow — Overall Study
MilestoneNalbuphine HCl ER
Started36
Completed16
Not completed20

Outcome measures

PrimaryOverall Incidence and Nature of Treatment Emergent Adverse Events (TEAEs)

Incidence of adverse events is calculated based on events observed on or after the date of first dose, where incidence is defined as the number of subjects who reported one or more events of a particular adverse event divided by the number of subjects who received at least one dose of investigational product. Overall incidence is the proportion of subjects who had one or more adverse events of any type and nature pertains to the incidence of individual events coded by MedDRA nomenclature. An additional consideration was to evaluate incidence of adverse events by dose achieved but this was not done as subjects achieved a maximum dose during the study that varied and, per protocol, dosing could be modified per the investigator, during the course of this extension to TR03. In addition, TR03EXT involved a dose titration whereas events could have been reported well before a subject achieved some partciular dose level. Consequently, such a presentation would have been impossible to discern.

Time frame:
50 weeks
Reported as:
Count of participants · Participants
Overall Incidence and Nature of Treatment Emergent Adverse Events (TEAEs)
ParticipantsNalbuphine HCl ER
Overall Incidence and Nature of Treatment Emergent Adverse Events (TEAEs)34

Adverse events

Collected over Adverse events collected beginning with the first date and time of dosing through up to 50 weeks of dosing.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nalbuphine HCl ER0/36 (0%)2/36 (5.6%)0/36 (0%)
Most frequent serious events
Most frequent serious events
EventNalbuphine HCl ER
BradycardiaCardiac disorders1/36
Joint injuryInjury, poisoning and procedural complications1/36
Tenosynovitis stenosansMusculoskeletal and connective tissue disorders1/36
Ulnocarpal abutment syndromeMusculoskeletal and connective tissue disorders1/36

Baseline characteristics

Age, Continuous
Age, Continuous(years)Nalbuphine HCl ER
Mean52.4 ± 13.2
Sex: Female, Male
Sex: Female, Male(Participants)Nalbuphine HCl ER
Female16
Male20
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nalbuphine HCl ER
Hispanic or Latino0
Not Hispanic or Latino36
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nalbuphine HCl ER
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American2
White33
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Nalbuphine HCl ER
United States5
Europe31
Height
Height(cm)Nalbuphine HCl ER
Mean172.33 ± 8.15
Weight
Weight(kg)Nalbuphine HCl ER
Mean79.68 ± 16.64
08

Study locations

1 site
  • University of Münster
    Münster, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2015 to primary completion in Sep 2017, 24 months.

Results were first posted in Oct 2020, 3 years 1 month after primary completion. A results delay was requested in Aug 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2014
First posted
Jun 25, 2014
StartActual
Aug 15, 2015
Primary completionActual
Sep 3, 2017
CompletionActual
Sep 3, 2017
Results delay requested
Aug 22, 2018
Results first posted
Oct 23, 2020
Last update
May 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02174432
Lead sponsor
Trevi Therapeutics
Responsible party
Sponsor
First posted
Jun 25, 2014
Start date
Aug 15, 2015
Primary completion
Sep 3, 2017
Completion
Sep 3, 2017
Results posted
Oct 23, 2020
Last update
May 21, 2025

Study contacts

Chief Development Officer
study director · Trevi Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nalbuphine

Start the discussion